1. Assessment of deep vein thrombosis prophylaxis in surgical patients: a study conducted at Nancy University Hospital, France

   • D. J. Lepaux
   • C. Charpentier
   • S. Briançon

   CLINICAL TRIALS Pages: 671 - 676

2. Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule

   • N. Perdaems
   • J. M. Bachaud
   • E. Chatelut

   CLINICAL TRIALS Pages: 677 - 683

3. Education in clinical pharmacology at the Rijeka School of Medicine, Croatia

   • V. Vlahović Palčevski
   • D. Vitezić
   • A. Simonić

   PHARMACODYNAMICS Pages: 685 - 689

4. Cardiovascular effects of mibefradil in hypertensive patients with obstructive sleep apnea

   • J. Heitmann
   • L. Grote
   • J.-H. Peter

   PHARMACODYNAMICS Pages: 691 - 696

5. Ciprofibrate treatment in patients with atherogenic lipoprotein phenotype: effects on HDL quality, LDL susceptibility to oxidation and DNA damage

   • K. Rašlová
   • M. Dobiášová
   • M. Dušinská

   PHARMACODYNAMICS Pages: 697 - 699

6. Drug-specific characteristics of thrombocytopenia caused by non-cytotoxic drugs

   • U. Pedersen-Bjergaard
   • M. Andersen
   • P. B. Hansen

   PHARMACODYNAMICS Pages: 701 - 706

7. Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects

   • S. M. Bode-Böger
   • R. H. Böger
   • J. C. Frölich

   PHARMACODYNAMICS Pages: 707 - 714

8. Pharmacokinetics of a novel 5-lipoxygenase inhibitor (ABT-761) in pediatric patients with asthma

   • S. L. Wong
   • G. L. Kearns
   • W. M. Awni

   PHARMACOKINETICS AND DISPOSITION Pages: 715 - 719

9. Assessment of the value of therapeutic monitoring of tacrine in Alzheimer's disease

   • C. J. C. Roberts
   • J. M. Ford
   • G. K. Wilcock

   PHARMACOKINETICS AND DISPOSITION Pages: 721 - 724

10. Estimation of the area under the concentration-versus-time curve of carboplatin following irinotecan using a limited sampling model

    • G. Asai
    • Y. Ando
    • K. Shimokata

    PHARMACOKINETICS AND DISPOSITION Pages: 725 - 727

11. Can oral contraceptive steroids influence the elimination of nifedipine and its primary pryidine metabolite in humans?

    • A. Balogh
    • S. Gessinger
    • M. Oettel

    PHARMACOKINETICS AND DISPOSITION Pages: 729 - 734

12. Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro

    • B. Buur Rasmussen
    • T. L. Nielsen
    • K. Brøsen

    PHARMACOKINETICS AND DISPOSITION Pages: 735 - 740

13. Neither dapsone hydroxylation nor cortisol 6β-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors

    • R. J. A. Gass
    • J. Gal
    • J. G. Gerber

    PHARMACOKINETICS AND DISPOSITION Pages: 741 - 747

14. Saliva-resistant coating of tablets prevents oral release of penicillin Plasma but not saliva equivalence

    • H. Quiding
    • H. G. Arwidsson
    • S. Holm

    PHARMACOKINETICS AND DISPOSITION Pages: 749 - 752

15. Interaction of citrus juices with pranidipine, a new 1,4-dihydropyridine calcium antagonist, in healthy subjects

    • K. Hashimoto
    • T. Shirafuji
    • J. Azuma

    PHARMOCOKINETICS AND DISPOSITION Pages: 753 - 760

16. The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone

    • T. S. Lamberg
    • K. T. Kivistö
    • P. J. Neuvonen

    PHARMACOKINETICS AND DISPOSITION Pages: 761 - 766

17. Pharmacokinetics and safety of propiverine in patients with fatty liver disease

    • M. Siepmann
    • A. Nokhodian
    • W. Kirch

    PHARMACODYNAMICS AND DISPOSITION Pages: 767 - 771

18. The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers

    • A. T. Melia
    • J. Zhi
    • J. Odink

    PHARMACOKINETICS AND DISPOSITION Pages: 773 - 777

19. The arylamine N-acetyltransferase (NAT2) polymorphism and the risk of adverse reactions to co-trimoxazole in children

    • E. Zielińska
    • W. Niewiarowski
    • J. Bodalski

    PHARMACOEPIDEMIOLOGY AND PRESCRIPTION Pages: 779 - 785

20. Genetic polymorphism of CYP2D6 in North Indian subjects

    • V. Lamba
    • J. K. Lamba
    • K. K. Kohli

    PHARMACOEPIDEMIOLOGY AND PRESCRIPTION Pages: 787 - 791

21. Drug treatment for hypertension in Finnish primary health care

    • S. Wallenius
    • E. Kumpusalo
    • J. Takala

    PHARMACOEPIDEMIOLOGY AND PRESCRIPTION Pages: 793 - 799

22. The teaching of pharmacology in Italian medical schools: the point of view of Italian doctors

    • M. Furlanut

    PHARMACOLOGY TEACHING Pages: 801 - 804

23. Skin absorption of Dexamphetamine base – a case report

    • P. Hartvig

    CASE REPORT Pages: 805 - 807

24. Acetylcholinesterase assay may predict cognitive response of Alzheimer patients to eptastigmine treatment

    • B. P. Imbimbo
    • M. Nicoli
    • G. Gambina

    LETTER TO THE EDITORS Pages: 809 - 810

25. Naproxen concentrations in articular tissues after prolonged treatment with naproxen sodium in patients with arthritis of the hip

    • B. Bannwarth
    • F. Lagrange
    • J. Dehais

    LETTER TO THE EDITORS Pages: 811 - 813

26. Life-threatening vasculitis related to quinidine occurring in a healthy volunteer during a clinical trial

    • D. Lipsker
    • S. Walther
    • B. Cribier

    LETTER TO THE EDITORS Pages: 815 - 815